Evidence map›Paper›PMID 31875247›Full record

ArticleWorld journal of urology2020

Outcomes of treatment for localized prostate cancer in a single institution: comparison of radical prostatectomy and radiation therapy by propensity score matching analysis.

Narihiko Hayashi, Kimito Osaka, Kentaro Muraoka, Hisashi Hasumi, Kazuhide Makiyama, Keiichi Kondo, Noboru Nakaigawa, Masahiro Yao, Yuki Mukai, Madoka Sugiura and 10 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in World journal of urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. The direct prognosis comparison ofEuropean journal of medical research · 2023
    Review
  9. Article
  10. Article
  11. Observational
  12. Biochemical failure and toxicity in treatment with brachytherapy and external beam radiotherapy compared with radical prostatectomy in localized prostate cancer.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2022
    Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 2 institutions in 1 country.

Narihiko HayashiDepartment of Urology, Yokohama City University, School of Medicine, Room A-625, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa, 236-0004, Japan. twnary@yahoo.co.jp.ORCID http://orcid.org/0000-0002-4776-5188
Kimito OsakaDepartment of Urology, Yokohama City University, School of Medicine, Room A-625, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa, 236-0004, Japan.
Kentaro MuraokaDepartment of Urology, Yokohama City University, School of Medicine, Room A-625, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa, 236-0004, Japan.
Hisashi HasumiDepartment of Urology, Yokohama City University, School of Medicine, Room A-625, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa, 236-0004, Japan.
Kazuhide MakiyamaDepartment of Urology, Yokohama City University, School of Medicine, Room A-625, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa, 236-0004, Japan.
Keiichi KondoDepartment of Urology, Yokohama City University, School of Medicine, Room A-625, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa, 236-0004, Japan.
Noboru NakaigawaDepartment of Urology, Yokohama City University, School of Medicine, Room A-625, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa, 236-0004, Japan.
Masahiro YaoDepartment of Urology, Yokohama City University, School of Medicine, Room A-625, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa, 236-0004, Japan.
Yuki MukaiDepartment of Radiation Oncology, Yokohama City University, School of Medicine, Yokohama, Japan.
Madoka SugiuraDepartment of Radiation Oncology, Yokohama City University, School of Medicine, Yokohama, Japan.
Shoko TakanoDepartment of Radiation Oncology, Yokohama City University, School of Medicine, Yokohama, Japan.
Eiko ItoDepartment of Radiation Oncology, Yokohama City University, School of Medicine, Yokohama, Japan.
Hisashi KaizuDepartment of Radiation Oncology, Yokohama City University, School of Medicine, Yokohama, Japan.
Izumi KoikeDepartment of Radiation Oncology, Yokohama City University, School of Medicine, Yokohama, Japan.
Masaharu HataDepartment of Radiation Oncology, Yokohama City University, School of Medicine, Yokohama, Japan.
Masataka TaguriDepartment of Biostatistics and Epidemiology, Yokohama City University, School of Medicine, Yokohama, Japan.
Yasuhide MiyoshiDepartment of Urology, Yokohama City University Medical Center, Yokohama, Japan.
Koji IzumiDepartment of Urology, Yokohama City University Medical Center, Yokohama, Japan.
Takashi KawaharaDepartment of Urology, Yokohama City University Medical Center, Yokohama, Japan.
Hiroji UemuraDepartment of Urology, Yokohama City University Medical Center, Yokohama, Japan.
Yokohama City University · JPYokohama City University Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo compare the outcomes of radical prostatectomy (RP), intensity-modulated radiation therapy (IMRT), and low-dose-rate brachytherapy (BT) using propensity score matching analysis in patients with clinically localized prostate cancer.

methodsA group of 2273 patients with clinically localized prostate cancer between January 2004 and December 2015 at the Yokohama City University hospital were identified. The records of 1817 of these patients, who were followed up for a minimum of 2 years, were reviewed; 462 were treated with RP, 319 with IMRT, and 1036 with BT. The patients were categorized according to the National Comprehensive Cancer Network risk classification criteria, and biochemical outcomes and overall survival rates were examined. Biochemical failure for RP was defined as prostate-specific antigen (PSA) levels > 0.2 ng/ml, and for IMRT and BT as nadir PSA level + 2 ng/ml. Propensity scores were calculated using multivariable logistic regression based on covariates, including the patient's age, preoperative PSA, Gleason score, number of positive cores, and clinical T stage.

resultsMedian follow-up was 77 months for the RP, 54 months for IMRT, and 66 months for BT patients. After the propensity scores were adjusted, a total of 372 (186 each) and 598 (299 each) patients were categorized into RP vs IMRT and RP vs BT groups, respectively. Kaplan-Meier analysis did not show any statistically significant differences in terms of overall survival rate between these groups (RP vs IMRT: p = 0.220; RP vs BT: p = 0.429). IMRT was associated with improved biochemical failure-free survival compared to RP in all risk groups (high-risk: p < 0.001; intermediate-risk: p = 0.009; low-risk: p = 0.001), whereas significant differences were observed only in the intermediate-risk group (p = 0.003) within the RP vs BT group.

conclusionThe results of our propensity score analysis of mid-term localized prostate cancer treatment outcomes demonstrated no significant differences in the overall survival rate. Despite the difference in biochemical failure definition between surgery and radiotherapeutic approaches, the results of this study demonstrate improved biochemical control favoring IMRT and BT as compared to RP.

Indexed as

BrachytherapyPropensity ScoreProstatectomyRadiotherapy, Intensity-ModulatedAgedHumansMaleMiddle AgedProstatic NeoplasmsRetrospective StudiesSurvival RateTreatment OutcomeBrachytherapyIntensity-modulated radiation therapyLocalized prostate cancerPropensity score matching analysisProstatectomy

Identifiers

PMID31875247
OpenAlexW2996800662

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.